Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus HYFTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus HYFTOR.
CAPEX vs HYFTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
HYFTOR (solithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation and inhibiting translation. It also exhibits anti-inflammatory effects by modulating cytokine production and neutrophil activity.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
0.5% gel, apply a thin layer to the treatment area once daily at bedtime. Duration: 4-8 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 5.5 hours (range: 3.2–9.1 h), supporting twice-daily dosing.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism; minimal renal excretion (<1% as unchanged drug). Eliminated via feces (84%) and urine (4%) as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid